Delivery Order SPE2DB22D1017-SPE2DB25FF6RF

Award Date 2/28/25
Potential Completion Date 3/3/25
Potential Value $17K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award from the Defense Logistics Agency (DLA) was issued to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $15,248.92 firm-fixed-price delivery order covers the supply of Descovy 200-25 mg tablets for an ultimate completion date of November 12, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This federal contract award, valued at $17,370.63, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order that provides the DLA with Descovy 200-25 MG Tablet, a pharmaceutical product, under a Firm Fixed Price pricing arrangement. The contract has an ultimate completion date of January 30, 2025 and does not have a set-aside designation, indicating open competition....
This federal contract award to Amerisourcebergen Drug Corp is a Delivery Order under a larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical, valued at $999,999,999 and running through November 2026. The order is for the pharmaceutical product Descovy 200-25 mg Tablet, with a ceiling value of $2,153.92 and a completion date of August 29, 2024. As a for-profit pharmaceutical distribution company, Amerisourcebergen is a key vendor for federal...
This federal contract award, valued at $8,154.13, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a delivery order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and...
This federal contract award, valued at $9,667.11, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Descovy 200-25 mg tablets, a pharmaceutical product, and has a completion date of June 10, 2024. The contract is a Firm Fixed Price Delivery Order, with no set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the...
This federal contract award, valued at $8,961.19, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the drug Descovy 200-25 mg tablet, with a completion date of December 12, 2023. The contract is a firm fixed-price type, with no set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the...
This federal contract award is a delivery order valued at $23,792.10 issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Descovy 200-25 mg tablets, a prescription medication, to support military healthcare programs. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
This federal contract award, valued at $17,203.55, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award covers the delivery of Descovy 200-25 mg Tablet, a prescription pharmaceutical product, to support defense and federal healthcare programs. The contract is a Firm Fixed Price Delivery Order, with a completion date of January 14, 2025. The award is not designated under any set-aside...
This federal contract award, valued at $7,361.80, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Descovy 200-25 mg tablet, a prescription medication, to support military healthcare programs. It is a firm-fixed-price delivery order contract with a completion date of January 28, 2025. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
This federal contract award, valued at $7,338.52, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a Delivery Order under the company's Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies...
  • SPE2DB22D1017
    Indefinite Delivery Contract
  • SPE2DB22D1017-SPE2DB25FF6RF
    Delivery Order

This federal contract award, valued at $16,941.50, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for Descovy 200-25 mg Tablet, a prescription medication, with a period of performance through March 3, 2025.

Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract encompasses critical medical commodities including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs.

This specific contract award was not designated with any set-aside requirements, indicating open competition.

Generated 5/30/25, 10:02 AM